Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda to Host Conference Call to Discuss Fourth Quarter and Year End 2015 Results on February 11, 2016

Business Wire January 28, 2016

Acorda to Acquire Biotie Therapies

Business Wire January 19, 2016

Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance and 2016/2017 Clinical Milestones at J.P. Morgan Healthcare Conference

Business Wire January 11, 2016

Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference

Business Wire December 22, 2015

Acorda Announces Departure of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. as Interim CMO

Business Wire December 21, 2015

Acorda Presents Analyses on Use of Healthcare Services for Seizure Clusters at American Epilepsy Society Annual Meeting

Business Wire December 8, 2015

Acorda Initiates Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines

Business Wire December 3, 2015

Acorda Therapeutics to Present at the Oppenheimer Annual Healthcare Conference

Business Wire November 30, 2015

Acorda Therapeutics to Present at Two Investor Conferences in November

Business Wire November 10, 2015

Acorda Provides Financial and Pipeline Update for 2015 Third Quarter

Business Wire October 22, 2015

Acorda Therapeutics to Host Conference Call to Discuss Third Quarter Results on October 22, 2015

Business Wire October 8, 2015

Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Business Wire October 7, 2015

Acorda Recognized with Legal Media Group 2015 Life Sciences Award

Business Wire October 2, 2015

Acorda Named One of the 100 Best Workplaces for Women by Fortune and Great Place to Work

Business Wire September 30, 2015

Acorda Therapeutics to Present at the Baird 2015 Healthcare Conference

Business Wire September 3, 2015

Acorda Announces Patent Trials and Appeal Board (PTAB) Denies Both IPRs of AMPYRA Patents

Business Wire August 24, 2015

Acorda Therapeutics to Present at the Canaccord Genuity Growth Conference

Business Wire August 5, 2015

Acorda Provides Financial and Pipeline Update for 2015 Second Quarter

Business Wire July 30, 2015

Acorda Therapeutics to Host Conference Call to Discuss Second Quarter Results on July 30, 2015

Business Wire July 23, 2015

Acorda Awarded Grant to Study ARCUS® Technology in Respiratory Distress Syndrome

Business Wire July 22, 2015